Survival Outcomes Among Patients With Gastric Adenocarcinoma Who Received Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery | Gastroenterology | JAMA Surgery | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.78.142. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Views 1,456
    Citations 0
    Research Letter
    June 12, 2019

    Survival Outcomes Among Patients With Gastric Adenocarcinoma Who Received Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery

    Author Affiliations
    • 1Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus
    JAMA Surg. 2019;154(8):780-782. doi:10.1001/jamasurg.2019.1698

    Gastric cancer (GC) with peritoneal metastases is associated with a poor prognosis. Median overall survival (OS) is less than 1 year with systemic chemotherapy alone.1 Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery (CRS) has been used for various peritoneal surface malignant tumors, and there has been marked interest in its application to GC because a small randomized clinical trial demonstrated improved OS among patients who underwent CRS-HIPEC compared with CRS alone.2 Although widespread adoption of HIPEC for GC has been limited because of poor oncologic outcomes and high perioperative morbidity,3 interest in the use of intraperitoneal chemotherapy for patients with advanced GC persists.1 We assessed survial outcomes among patients with gastric adenocarcinoma who received CRS-HIPEC at academic centers across the United States.

    ×